The Lancet Oncology
Издатель: Elsevier · ISSN 1470-2045 · 83 статей
- Brazil improves access to cancer screening and care
- Sweating the details in exercise oncology
- Iberdomide for minimal residual disease-negative myeloma—from underdog to the spotlight
- Time to say goodbye to full-field digital mammography in population-based screening?
- Comprehensiveness of national cancer control plans
- The unfulfilled promise of effective cancer medicines priced beyond reach
- Rare earth elements and the fragile promise of cancer theranostics
- Why childhood cancer medicines need market shaping led by the Global Platform: toward market transformation
- From biomarker actionability to surveillance utility in SERENA-6
- BCG-unresponsive non-muscle-invasive bladder cancer
- BCG-unresponsive non-muscle-invasive bladder cancer – Authors’ reply
- 70th IAEA General Conference
- India reaches 8 million milestone in HPV campaign
- US EPA repeals emission limits
- Could Brazil's tuberculosis network detect lung cancer earlier?
- New UK National Cancer Board
- Viet Nam considers health insurance for cancer screening
- 2026 ASTRO Annual Meeting
- Impact of the Trump Administration on the Affordable Care Act
- Europe has fallen behind in number of oncology trials
- Russia slashes federal cancer funding to spend on defence
- Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial
- Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
- Assessment of comprehensiveness of national cancer control plans using a multiagent artificial intelligence model: a global analysis
- Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study
- Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial
- Global uptake of essential cancer medicines with and without complex genomic diagnostics: a retrospective observational study
- Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
- Global health expenditures on cancer control: a cross-sectional analysis
- Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer